Valerie Ceva

COO and founder of clinical stage biotechnology company commercializing groundbreaking medical discoveries in inflammation and infection. The company is currently conducting a 600 subject, global Phase 2b study in 13 countries for Acute Respiratory Distress Syndrome (ARDS). Additional inflammatory indications are expected to enter the clinic in 2025.

Azure Biotech, Inc. is a private, newly formed biotechnology company which has acquired rights for development of a novel formulation of lasofoxifene, a selective receptor modulator (SERM) targeting an underserved market in women's health. Azure plans to rapidly build upon the extensive safety and efficacy data already available from trials completed with an oral formulation in more than 15,000 women. The team is uniquely qualified to bring lasofoxifene forward for the targeted new indications and formulations.

Provides strategy and management consulting to the pharmaceutical, biotechnology and venture firms. Develops new strategies and operational plans to address complicated issues across the Life Sciences value chain

Supported venture capital firms in strategy development and investment identification and emerging companies in business model development, venture capital acquisition and operational execution. Recent work included projects in biodefense, biotechnology and ehealth i.e. alternate care b2b ecommerce, supply chain optimization solutions and disease management software companies. Partner at Homeland Defense Ventures.

Post merger integration activities including leading process redesign initiatives and set and validated overall strategic direction for the US Pharmaceutical Division

Managed accounts corporate and regional accounts including leading HMOs, PBMs, PPMs, LTC GPOs, Medicaid Managed Care and Integrated Health Systems. Led development, negotiation, execution and implementation of integrated, multiproduct, performance-based contracts. Developed and led implementation of comprehensive co-marketing/ pull-through programs

Participated as key member of Accel Partner’s healthcare/life sciences venture capital team and as member of the California bay area venture community.

Internal consultant and strategist. Responsible for business development and equity investment for US Pharma and subsidiaries. Co-managed turnaround and reorganization of Geneva Pharmaceutical, developed Generic Transition (lifecycle management) Strategy, completed a major generic injectable joint venture, led US Pharma Research Strategy.